News | December 16, 2025
Anova launches AI-powered patient matching platform to speed clinical trial enrollment
Clinical trial enrollment has long been a bottleneck in drug development
Clinical trial enrollment has long been a bottleneck in drug development
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
Subscribe To Our Newsletter & Stay Updated
